Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4965-4970

  Gallegos, Alfred ^a   Berggren, Margareta ^a   Gasdaska, John R ^a   Powis, Garth ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SELENIUM; THIOREDOXIN REDUCTASE;

ARTICLE; CANCER CELL; DIET SUPPLEMENTATION; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANTICARCINOGENIC AGENTS; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; RNA, MESSENGER; SODIUM SELENITE; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH); TUMOR CELLS, CULTURED;

EID: 0030731916     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Golczewski, J. A., and Frenkel, G. D. Cellular selenoproteins and the effects of selenite on cell proliferation. Biol. Trace Element Res., 20: 115-126, 1989.
2. Burney, P. G., Comstock, G. W., and Morris, J. S. Pancreatic cancer. J. Clin. Nutr., 49: 895-900, 1997.
3. Glattre, E., Thomassen, Y., Haldorsen, T., Lund-Larsen, P. G., Theodorsen, L., and Aaseth, J. Prediagnostic serum selenium in a case-control study of thyroid cancer. Int. J. Epidemiol., 18: 45-49, 1989.
4. Jaskiewicz, K., Marasas, W. F. O., Rossouw, J. E., Van Niekrk, F. E., and Heine Tech Dip, E. W. P. Selenium and other mineral elements in populations at risk for esophageal cancer. Cancer (Phila.), 62: 2635-2639, 1988.
5. Knekt, P., Aromaa, A., Maatela, J., Alfthan, G., Aaran, R., Hakama, M., Kahulinin, T., Peto, R., and Teppo, L. Serum selenium and subsequent risk of cancer among Finnish men and women. J. Natl. Cancer Inst., 82: 864-868, 1990.
6. Philipou, P., and Tzatchev, K. Selenium concentrations in serum of patients with cerebral and extracerebral tumors. Zentralbl. Neurochir., 49: 344-347, 1988.
7. Westin, T., Ahlbom, E., Johansson, E., Sandstrom, B., Karlbert, I., and Edstrom, S. Circulating levels of selenium and zinc in relation to nutritional status in patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg., 115: 1079-1082, 1989.
8. Medina, D., and Morrison, D. G. Current ideas on selenium as a chemopreventive agent. Pathol. Immunopathol. Res., 7: 187-199, 1988.
9. Combs, G. F., Jr., and Clark, L. C. Selenium and cancer prevention. In: H. Garewal (ed.), Antioxidant Nutrients and Disease Prevention, pp. 97-113. Boca Raton: CRC Press, 1997.
10. Clark, L. C., Combs, G. F., Jr., Turnbull, B. W., Slate, E. H., Chalker, D. K., Chow, J., Davis, L. S., Glover, R. A., Graham, G. F., Gross, E. G., Krongrad, A., Lesher, J. L., Park, H. K., Sanders, B. B., Jr., Smith, C. L., and Taylor, J. R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized clinical trial. J. Am. Med. Assoc., 276: 1957-1963, 1996.
11. Thompson, H. J., Wilson, A., Lu, J., Singh, M., Jiang, C., Upadhyaya, P., El-Bayoumy, K., and Ip, C. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis (Lond.), 15: 183-186, 1994.
12. Milner, J. A. Effect of selenium on virally induced and transplantable tumor models. Fed. Proc., 44: 2568-2572, 1985.
13. Stadtman, T. C. Selenocysteine. Annu. Rev. Biochem., 65: 83-100, 1996.
14. Lane, H. W., and Medina, D. Selenium concentration and glutathione peroxidase activity in normal and neoplastic development of the mouse mammary gland. Cancer Res., 43: 1558-1561, 1983.
15. Gladyshev, V. N., Jeang, K., and Stadtman, T. C. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA, 93: 6146-6174, 1996.
16. Tamura, T., and Stadtman, T. C. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. USA, 93: 1006-1011, 1996.
17. Gasdaska, P. Y., Gasdaska, J. R., Cochran, S., and Powis, G. Cloning and sequencing of human thioredoxin reductase. FEBS Lett., 373: 5-9, 1995.
18. Gasdaska, P. Y., Oblong, J. E., Cotgreave, I. A., and Powis, G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim. Biophys. Acta, 1218: 292-296, 1994.
19. Laurent, T. C., Moore, E. C., and Reichard, P. Enzymatic synthesis of deoxyribonucleotides. VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem., 239: 3436-3444, 1964.
20. Matthews, J. R., Wakasugi, N., Virelizier, J-L., Yodoi, J., and Hay, R. T. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulphide bond involving cysteine 62. Nucl. Acids Res., 20: 3821-3830, 1992.
21. Cromlish, J. A., and Roeder, R. G. Human transcription factor IIIC (TFIIIC). Purification, polypeptide structure, and the involvement of thiol groups in specific DNA binding. J. Biol. Chem., 264: 18100-18109, 1989.
22. Bannister, A. J., Cook, A., and Kouzarides, T. In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Oncogene, 6: 1243-1250, 1991.
23. Grippo, J. F., Tienrungroj, W., Dahmer, M. K., Housley, P. R., and Pratt, W. B. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. J. Biol. Chem., 258: 13658-13664, 1983.
24. Gasdaska, J. R., Berggren, M., and Powis, G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ., 6: 1643-1650, 1995.
25. Oblong, J. E., Berggren, M., Gasdaska, P. Y., and Powis, G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J. Biol. Chem., 269: 11714-11720, 1994.
26. Fujii, S., Nanbu, Y., Nonogaki, H., Konishi, I., Mon, T., Masutani, H., and Yodoi, J. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer (Phila.), 68: 1583-1591, 1991.
27. Nakamura, H., Masutani, H., Tagaya, Y., Yamauchi, A., Inamoto, T., Nanbu, Y., Fujii, S., Ozawa, K., and Yodoi, J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer (Phila.), 69: 2091-2097, 1992.
28. Berggren, M., Gallegos, A., Gasdaska, J. R., Gasdaska, P. Y., Wameke, J., and Powis, G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res., 16: 3459-3466, 1996.
29. Gallegos, A., Gasdaska, J. R., Taylor, C. W., Paine-Murrieta, G. D., Goodman, D., Gasdaska, P. Y., Berggren, M., Briehl, M. M., and Powis, G. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells. Cancer Res., 56: 5765-5770, 1996.
30. Baker, A., Briehl, M., Payne, C., and Powis, G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res., in press, 1997.
31. Berggren, M., Gallegos, A., Gasdaska, J., and Powis, G. Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res., in press, 1997.
32. Oblong, J. E., Gasdaska, P. Y., Sherrill, K., and Powis, G. Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy. Biochemistry, 32: 7271-7277, 1993.
33. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
34. Briehl, M. M., Cotgreave, I. A., and Powis, G. Downregulation of the antioxidant defense during glucocorticoid-mediated apoptosis. Cell Death Differ., 2: 41-46. 1995.
35. Nelson, R. L., Davis, F. G., Sutler, E., Kikendall, J. W., Sobin, L. H., Milner, J. A., and Bowen, P. E. Serum selenium and colonie neoplastic risk. Dis. Colon Rectum, 38: 1306-1310, 1995.
36. Berry, M. J., Banu, L., and Larsen, P. R. Type I iodothyronine deiodinase is a selenocysteine-containing enzyme. Nature (Lond.), 349: 438-440, 1991.
37. Spyrou, G., Bjornstedt, M., Skog, S., and Holmgren, A. Selenite and selenate inhibit human lymphocyte growth via different mechanisms. Cancer Res., 56: 4407-4412, 1996.
38. Arscott, L. D., Gromer, S., Schirmer, R. H., Becker, K., and Williams, C. H., Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc. Natl. Acad. Sci. USA, 94: 3621-3623, 1997.
39. DePalo, D., Kinlaw, W. B., Zhao, C., Engelberg-Kulka, H., and St. Germain, D. L. Effect of selenium deficiency on type I 5′-deodinase. J. Biol. Chem., 269: 16223-16228, 1994.
40. Berry, M. J., Harney, J. W., Ohama, T., and Hatfield, D. L. Selenocysteine insertion or termination: factors affecting UGA codon fate and complementary anticodon: codon mutations. Nucl. Acids Res., 22: 3753-3759, 1994.
41. Low, S. C., and Berry, M. J. Knowing when not to stop: Selenocysteine incorporation in eukaryotes. Trends Biochem. Sci., 21: 203-207, 1996.
42. McCaughan, K. K., Brown, C. M., Dalphin, M. E., Berry, M. J., and Tate, W. P. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc. Natl. Acad. Sci. USA, 92: 5431-5435, 1995.
43. Baker, R. D., Baker, S. S., LaRosa, K., Whitney, C., and Newburger, P. E. Selenium regulation of glutathione peroxidase in human hepatoma cell line Hep3B. Arch. Biochem. Biophys., 304: 53-57, 1993.
44. Berry, M. J., and Larsen, P. R. The role of selenium in thyroid hormone action. Endocr. Rev., 13: 207-219, 1992.
45. Tanaka, H. O., and Stadtman, T. C. Selenium-dependent clostridial glycine reductase. Purification and characterization of the two membrane-associated protein components. J. Biol. Chem., 254: 447-452, 1979.
46. Hill, K. E., McCollum, G. W., Boeglin, M. E., and Burk, R. F. Thioredoxin reductase activity is decreased by selenium deficiency. Biochem. Biophys. Res. Commun., 234: 293-295, 1997.
47. Karplus, P. A., and Schulz, G. E. Substrate binding and catalysis by glutathione reductase as derived from refined enzyme: substrate crystal structures at 2Å resolution. J. Mol. Biol., 210: 163-180, 1989.
48. Hickman, J. A., Potten, C. S., Merritt, A. J., and Fisher, T. C. Apoptosis and cancer chemotherapy. Philos. Trans. R. Soc. Lond. B Biol. Sci., 345: 319-325, 1994.
49. Bedi, A., Pasricha, P. J., Akhtar, A. J., Barber, J. P., Bedi, G. C., Giardiello, F. M., Zehnbauer, B. A., Hamilton, S. R., and Jones, R. J. Inhibition of apoptosis during development of colorectal cancer. Cancer Res., 55: 1811-1816, 1995.
50. McDonnell, T. J., Meyn, R. E., and Robertson, L. E. Implications of apoptotic cell death regulation in cancer therapy. Semin. Cancer Biol., 6: 53-60, 1995.
51. Hu, Y. Studies on the correlation of blood selenium and lung cancer. II. An analysis of serum selenium levels and influencing factors in patients with lung cancer. Chinese J. Oncol., 14: 346-349, 1993.
52. Lange, J. H. Reanalysis of epidemiological data for selenium anti-cancer activity. Toxicol. Ind. Health, 7: 319-325, 1991.
53. Yang, G. Q., Wang, S. Z., Zhou, R. H., and Sun, S. Z. Endemic selenium intoxication of humans in China. Am. J. Clin. Nutr., 37: 872-881, 1983.